Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Managing EV & pembrolizumab related toxicities in bladder cancer

Stefanie Zschaebitz, MD, Heidelberg University Hospital, Heidelberg, Germany, gives an overview on the main adverse events associated with enfortumab vedotin (EV) and pembrolizumab, highlighting polyneuropathy and dermatotoxicity as the primary concerns. Patients need to be closely monitored for these toxicities, making adjustments as needed, and treatment should cease if polyneuropathy worsens, where approximately one in ten patients have to stop treatment due to this side effect. Dermatological toxicity can be challenging to manage, requiring a trial-and-error approach and often topical treatment to alleviate symptoms. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

What are the main toxicities? The main toxicities are polyneuropathy and dermatotoxicity. Regarding polyneuropathy, I think it’s very important to closely look at your patient, talk to the patient and make those modifications. Also, interrupt treatment permanently if neuropathy greater or higher occurs. and that happened to 10% of our patients that had to stop AV due to PNP...

What are the main toxicities? The main toxicities are polyneuropathy and dermatotoxicity. Regarding polyneuropathy, I think it’s very important to closely look at your patient, talk to the patient and make those modifications. Also, interrupt treatment permanently if neuropathy greater or higher occurs. and that happened to 10% of our patients that had to stop AV due to PNP. Regarding dermatotoxicity, sometimes it’s not so easy to distinguish which is the main agent that causes the toxicity. Sometimes it’s a little bit of trial and error, so you may restart one treatment and then the other, and mostly topical treatment is sufficient for treating those toxicities. Thank you.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...